Artificial intelligence news and machine learning news

How AI is shaping clinical research and trials

Willow Shah-Neville — Fri, 21 Jul 2023 10:31:56 +0000

Artificial intelligence (AI) is everywhere at the minute, seemingly being used in some capacity in almost every professional industry, including clinical research and trials. In fact, it is fair to say that AI has taken the biotech industry by storm, and the hype surrounding it has led to numerous AI startup companies coming onto the […]

The post How AI is shaping clinical research and trials appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Life saved: AI discovers existing drug works for rare disease

Jim Cornall — Fri, 14 Jul 2023 09:45:00 +0000

A patient’s life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, and Every Cure, used artificial intelligence to use an existing drug to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to unlock new uses for existing medicines across […]

The post Life saved: AI discovers existing drug works for rare disease appeared first on Labiotech.eu.

AI program finds multiple influenza drug targets

Jim Cornall — Thu, 29 Jun 2023 09:48:48 +0000

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]

The post AI program finds multiple influenza drug targets appeared first on Labiotech.eu.

SandboxAQ launches new division to boost drug development

Jim Cornall — Fri, 23 Jun 2023 08:13:19 +0000

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

The post SandboxAQ launches new division to boost drug development appeared first on Labiotech.eu.

BIO International Convention 2023: The Highlights

Dylan Kissane — Tue, 20 Jun 2023 12:00:00 +0000

BIO International Convention, one of the largest networking events hosted for the biotech industry, has been influential in helping biopharmas discover new opportunities and building and strengthening partnerships within the biotech and pharma community. This year, the event took place from June 5 to 8, in the bustling biotech hotspot of Boston, Massachusetts, and saw […]

The post BIO International Convention 2023: The Highlights appeared first on Labiotech.eu.

Can ChatGPT be used to advance drug discovery?

Willow Shah-Neville — Fri, 16 Jun 2023 10:00:00 +0000

Chat GPT – which is a large language model (LLM) and belongs to a family of artificial intelligence (AI) known as generative AI – has been a revelation for many people around the world, and, since its launch, has been used by professionals in many industries to assist with work-related tasks, such as editing and […]

The post Can ChatGPT be used to advance drug discovery? appeared first on Labiotech.eu.

How AI can advance research and treatment of CNS disorders

External Contributor — Tue, 13 Jun 2023 12:13:47 +0000

By Xiao Xu, senior research fellow, Cerevance The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders. By leveraging AI’s computational power, researchers have been able to interrogate diverse datasets to provide insights into disease mechanisms, discover novel therapeutic compounds, detect […]

The post How AI can advance research and treatment of CNS disorders appeared first on Labiotech.eu.

How Ireland connects AI and life sciences

Jim Cornall — Wed, 07 Jun 2023 11:28:01 +0000

Depending on your point of view, artificial intelligence (AI) can create jobs, make life easier, and solve many global problems; or, it’s going to cause mass unemployment, take over the world, and enslave humanity. In the life sciences space, AI is capable of tackling some of the biggest challenges when it comes to tasks like […]

The post How Ireland connects AI and life sciences appeared first on Labiotech.eu.

Optimizing early discovery by unraveling cancer complexity within precision therapeutics

Sudha Sundaram — Tue, 06 Jun 2023 08:00:05 +0000

The post Optimizing early discovery by unraveling cancer complexity within precision therapeutics appeared first on Labiotech.eu.

Artificial intelligence combats lethal superbug, new antibiotic discovered

Roohi Mariam Peter — Wed, 31 May 2023 08:07:09 +0000

A new antibiotic called abaucin that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed that AI was able to rapidly screen 7,500 molecules that were found to inhibit the growth of the superbug Acinetobacter baumannii, a task that would be […]

The post Artificial intelligence combats lethal superbug, new antibiotic discovered appeared first on Labiotech.eu.

Report: Outsourcing in Life Science R&D Today

Alexander Burik — Tue, 16 May 2023 10:21:25 +0000

Over the last twenty years, life science companies started outsourcing large portions of their R&D activities to external suppliers, including complex, specialized services that were traditionally performed in-house. Outsourcing has become an integral part of life science R&D over the last two decades. There are several reasons for this shift. The cost of drug development […]

The post Report: Outsourcing in Life Science R&D Today appeared first on Labiotech.eu.

LabGenius looks to create molecules with huge increase in tumor killing ability

Jim Cornall — Tue, 16 May 2023 10:00:00 +0000

LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […]

The post LabGenius looks to create molecules with huge increase in tumor killing ability appeared first on Labiotech.eu.

Achilles Therapeutics’ new platform identifies most potent T-cell antigens

Jim Cornall — Fri, 12 May 2023 10:43:37 +0000

Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […]

The post Achilles Therapeutics’ new platform identifies most potent T-cell antigens appeared first on Labiotech.eu.

Recursion boosts drug discovery with Cyclica and Valence acquisitions

Jim Cornall — Tue, 09 May 2023 10:00:00 +0000

Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt Lake City headquartered Recursion, said: “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology […]

The post Recursion boosts drug discovery with Cyclica and Valence acquisitions appeared first on Labiotech.eu.

Generative AI in novel drug development

Sachin Rawat — Tue, 02 May 2023 08:15:22 +0000

Within months of its release, ChatGPT is finding use in almost all industries, including biotech, pharma, and healthcare. ChatGPT and other large language models like it belong to a family of artificial intelligence (AI) technologies dubbed generative AI. Based on statistical associations gathered from large datasets, generative AI models produce content similar to the data […]

The post Generative AI in novel drug development appeared first on Labiotech.eu.

Beyond Biotech podcast 43

Jim Cornall — Fri, 28 Apr 2023 10:05:09 +0000

This week’s podcast is sponsored by Scientist.com. The mainstream media in the past couple of months has picked up on artificial intelligence (AI). The coverage concentrates not so much on its uses, more it highlights the potential for conflict, and fears over AI developing too quickly, or ‘taking over humanity.’ Debates have sprung up around […]

The post Beyond Biotech podcast 43 appeared first on Labiotech.eu.

Australian biopharma Telix banks on AI with Dedicaid acquisition

Jim Cornall — Thu, 27 Apr 2023 11:08:27 +0000

Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […]

The post Australian biopharma Telix banks on AI with Dedicaid acquisition appeared first on Labiotech.eu.

Can artificial intelligence predict future pandemics?

Jim Cornall — Fri, 21 Apr 2023 08:29:06 +0000

Before the first cases of COVID-19 became known, an algorithm based on artificial intelligence developed by a company in Canada had already detected a new virus spreading across the Chinese city of Wuhan. This demonstration of the potential of new technologies applied to predicting future epidemics led a group of researchers at the Universitat Oberta […]

The post Can artificial intelligence predict future pandemics? appeared first on Labiotech.eu.

Pharmacovigilance – how to deal with the data

External Contributor — Tue, 18 Apr 2023 10:53:29 +0000

By Axel Hagel, practice leader, PV & RM services, IQVIA Life science data, especially safety data, is exploding. It is estimated that pharmaceutical data is increasing at a rate of 36% annually. This is more than other data-driven industries including finance (26% YoY) and manufacturing (30% YoY). This increase is in part due to digital […]

The post Pharmacovigilance – how to deal with the data appeared first on Labiotech.eu.

Adaptyv Bio launches to ‘change protein engineering’

Jim Cornall — Thu, 13 Apr 2023 09:30:00 +0000

AI tools like ChatGPT are revolutionizing how the world generates text, images and code. In a similar way, machine learning algorithms and generative AI are upending traditional processes in life sciences and collapsing time frames in drug discovery and materials development. AlphaFold by DeepMind is probably the most well-known machine learning model in this space. […]

The post Adaptyv Bio launches to ‘change protein engineering’ appeared first on Labiotech.eu.